NCT06919965 - A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer | Biotech Hunter

Enrollment

220

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

August 13, 2027

Study Completion Date

March 16, 2032

Conditions

Non-Muscle Invasive Bladder Neoplasms

Interventions

DRUG

TAR-210

TAR-210 will be administered intravesically.

DRUG

Mitomycin C

MMC will be administered intravesically.

DRUG

Gemcitabine

Gemcitabine will be administered intravesically.

Trial Locations (13)

13620

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

30328

RECRUITING

Georgia Urology, Atlanta

38138

RECRUITING

The Conrad Pearson Clinic, Germantown

44130

RECRUITING

Helios Clinical Research, LLC, Middleburg Heights

52621

RECRUITING

Sheba Medical Center, Ramat Gan

78745

RECRUITING

Urology Austin, Austin

300211

RECRUITING

The Second Hospital Of Tianjin Medical University, Tianjin

315020

RECRUITING

The First Affiliated Hospital of Ningbo University, Ningbo

3109601

RECRUITING

Rambam Medical Center, Haifa

040 8611

RECRUITING

Hakodate Goryoukaku Hospital, Hakodate

232 0024

RECRUITING

Yokohama City University Medical Center, Yokohama

06351

RECRUITING

Samsung Medical Center, Gangnam Gu

SM2 5PT

RECRUITING

Royal Marsden Hospital, Surrey

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY